Another BsAb being investigated in T-cell lymphomas is the anti-PD-1/CD3 BsAb ONO-4685, which aims to augment T-cell-mediated destruction of malignant cells. This evidence concerns the gene PDCD1 and T-cell non-Hodgkin lymphoma.